What breaks when pharma networks stay flat under zero trust?

Where flat networks break zero trust in pharma environments

zero trust is not just about stronger login checks, it is about limiting what any one identity, device, or process can reach once it is inside. In a flat pharma network, that containment layer is missing, so a compromise in a low-value zone can still touch systems that should have been isolated for research, quality, manufacturing, or clinical operations. That weakens the basic zero trust assumption that every access path should be narrow and explicit.

A flat design also makes policy enforcement harder because segmentation, per-application trust boundaries, and conditional access decisions have nowhere meaningful to operate. If the network does not separate laboratory systems, plant systems, office systems, and third-party access paths, zero trust becomes a label on top of broad reach rather than a control model that reduces blast radius. The practical failure is not that zero trust is absent in theory, but that the environment still behaves like a shared trust zone.

For pharma, that matters because different environments carry different operational and regulatory consequences. A workstation compromise is not just an IT event if it can pivot toward manufacturing execution, lab instruments, batch records, or sensitive trial data. The more uniform the network, the easier it is for malware to move laterally without meeting a new trust boundary that would slow it down or expose it.

That is why segmentation guidance matters here. NIST SP 800-207 Zero Trust Architecture frames the core requirement correctly: trust should be evaluated per request, with access narrowed to the specific resource and context. In a pharma setting, the architectural implication is that the network must enforce those boundaries rather than assume them.

Why lateral movement becomes the real failure mode

When a network stays flat, the main risk is not only initial compromise but what happens next. Ransomware, malware, credential misuse, and unauthorized operator access can all use the same broad east-west pathways to spread from ordinary office assets into more critical zones. The result is a bigger attack surface inside the perimeter, even if the perimeter itself looks intact.

Flatness also makes compromise harder to contain because defenders lose the ability to isolate by business function or system criticality. If the same broadcast domain or routing domain carries user devices, shared services, and operational technology support systems, incident response becomes a race against propagation. Containment then depends on finding the problem first, rather than on architecture that already limited the path.

This is where workload and service boundaries matter as much as user boundaries. Guide to SPIFFE and SPIRE is useful because it shows how workload identity, attestation, and trust bundles can support tighter service-to-service trust than a flat network can provide on its own. In other words, segmentation and identity need to work together if east-west movement is to be meaningfully constrained.

Flat networks also create a false sense of resilience. They can look simple to operate, but simplicity turns into fragility when one foothold can reach too much. In a regulated production environment, that can turn a localized problem into a site-wide interruption, because the same compromise path reaches shared services, production support tools, and downstream systems that were never intended to share equivalent trust.

On the operational side, this is exactly why containment and least privilege should be designed together. Zero Trust Identity Guide is a good fit for the access model because it ties identity-centric policy to zero trust execution across people, workloads, and devices.

What pharma teams should do before calling the design zero trust

A pharma network is only materially aligned with zero trust when it can prove that compromise in one zone does not automatically grant reach into another. That means the first check is not whether a zero trust product is present, but whether the environment has clear segmentation around office IT, laboratories, manufacturing, clinical, and vendor-access pathways. If those zones are still broadly routable, the design is not yet delivering the containment zero trust promises.

The next check is whether critical systems can still be reached through shared administration paths, shared authentication paths, or flat east-west trust between workloads. If the answer is yes, then the architecture may have reduced some perimeter risk but has not eliminated lateral movement risk. At that point, the right question is where the trust boundary actually exists, not whether the environment has been labeled zero trust.

For teams trying to prioritize remediation, the most useful sequence is: map the highest-consequence zones first, isolate them from general-purpose office traffic, then validate that service access is explicitly allowed rather than inherited from network adjacency. That sequence is more defensible than trying to rewrite the whole network at once, because it focuses effort on the paths an attacker would most value.

Organisations also underestimate how often segmentation failures come from operational convenience rather than technical impossibility. Shared subnets, shared jump paths, and broad admin exceptions can quietly restore the very reach zero trust is supposed to remove. The practical discipline is to treat any exception that can touch regulated or production systems as a temporary risk decision, not a standing architecture choice.

What to prioritise: Start with the zones that would create the highest blast radius if compromised, then verify that those zones cannot be reached through general office trust or reused admin paths.

What to verify: Confirm that a single endpoint compromise cannot reach laboratory, manufacturing, or clinical assets without passing a separate policy decision and an explicit allow rule.

Practitioner takeaway: If a flat network can still pivot freely across pharma functions, zero trust is not failing at authentication, it is failing at containment.

Practitioner takeaway: If a flat network can still pivot freely across pharma functions, zero trust is not failing at authentication, it is failing at containment.

Related resources from NHI Mgmt Group

• What breaks when security operations stay manual during a zero trust rollout?
• What breaks when healthcare networks still rely on flat internal trust?
• What breaks when certificate management stays manual in a Zero Trust programme?
• What breaks when organisations assume SASE automatically delivers Zero Trust?